Understanding these mechanisms helps providers differentiate between expected adjustment-phase dizziness and signals requiring immediate clinical attention
Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies
Man, I love exclamation marks
New research suggests that patients taking a semaglutide, such as Rybelsus, may be at a higher risk of developing severe vision problems, including Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
These findings suggest a potential protective role for GLP-1 signaling in modulating orbital inflammation, though prospective trials are required for confirmation
Related articles Hanmi files for approval of new GLP-1 weight-loss shot, tees up diabetes and DTx expansions Hanmis obesity drug that 'adds muscle while losing fat' wins FDA OK for phase 1 Hanmi Pharm files FDA IND for obesity drug that targets fat loss and muscle gain Hanmi Pharm files phase 3 IND for GLP-1 combo in type 2 diabetes Hanmi Pharms MK-6024 eases concerns, targets game-changing MASH opportunity FDA grants breakthrough status to Hanmis congenital hyperinsulinism drug Hanmi Pharm smashes records with 1.54 tril
